Answers are grounded in this paper and cite their sources.
Background Anti-neurofascin-155 (NF155) IgG4 autoimmune nodopathy (AN) is an autoimmune neuropathy involving dysfunction of the nodes of Ranvier or paranodal regions. This condition is distinct from chronic inflammatory demyelinating polyneuropathy. Pediatric cases are rare, and longitudinal data linking antibody titers to the clinical course are limited. Case presentation A 12-year-old girl who was initially diagnosed with chronic inflammatory demyelinating polyneuropathy developed distal-dominant muscle weakness. Intravenous immunoglobulin and high-dose methylprednisolone, followed by oral prednisolone, were not effective, and selective plasma exchange resulted in modest and transient improvement only. The subsequent detection of anti-NF155 antibodies in the serum and cerebrospinal fluid led to the diagnosis of AN. A single intravenous dose of rituximab (RTX) 500 mg produced significant clinical and electrophysiologic improvements and resulted in a decline in antibody titer levels. Discussion/conclusion In the current case, the patient's antibody titer levels decreased in parallel with recovery. Thereafter, her titer levels increased modestly without overt clinical worsening, thereby indicating that titer changes should be examined along with clinical and electrophysiologic follow-up. This case supports the efficacy of RTX and suggests that serial measurement of anti-NF155 antibody titers can be a helpful adjunct to clinical and electrophysiologic assessment in pediatric AN.
No takes yet. Share an insight, caveat, or question.
Oteki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: